Lancaster, Lisa H.
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Received: 27 February 2018
Accepted: 5 November 2018
First Online: 13 December 2018
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: The author has served on advisory boards for Genentech, Global Blood Therapeutics, Boehringer Ingelheim, Veracyte, Theravance, Magnolia Therapeutics, Galapagos, and Bellerophon; has provided disease state education for Genentech and Boehringer Ingelheim; has served as a principal investigator in clinical trials in IPF and ILD for Genentech, Global Blood Therapeutics, Celgene, FibroGen, Stromedix, Veracyte, Afferent, Merck, Bellerophon, Novartis, Galapagos, Galecto, the National Institutes of Health, and Boehringer Ingelheim.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.